rolipram and Asthma
rolipram has been researched along with Asthma in 46 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the influence of pretreatment with the phosphodiesterase-4 inhibitor rolipram on pulmonary resistance, influx of inflammatory cells, and histamine concentration in bronchoalveolar lavage fluid (BALF) during an experimental asthmatic reaction induced in ovalbumin (OA)-sensitized guinea pigs, challenged with OA inhalation." | 7.73 | Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. ( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006) |
| " Theophylline possesses anti-inflammatory activities in asthma." | 7.72 | Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003) |
| " Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD)." | 3.77 | Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. ( Chen, CM; Han, CY; Hsu, HT; Ko, WC; Wang, KH; Yang, YL, 2011) |
| "The aim of this study was to evaluate the influence of pretreatment with the phosphodiesterase-4 inhibitor rolipram on pulmonary resistance, influx of inflammatory cells, and histamine concentration in bronchoalveolar lavage fluid (BALF) during an experimental asthmatic reaction induced in ovalbumin (OA)-sensitized guinea pigs, challenged with OA inhalation." | 3.73 | Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. ( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006) |
| " Theophylline possesses anti-inflammatory activities in asthma." | 3.72 | Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003) |
| "The aim of this study was to establish a conscious guinea-pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels." | 3.72 | Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram. ( Broadley, KJ; Toward, TJ, 2004) |
| "PBMCs from control subjects and allergic asthmatic patients were stimulated with PHA in the presence of low doses of fluticasone propionate (FP) with or without salmeterol for 72 hours." | 3.72 | Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. ( Dunlap, A; Goleva, E; Leung, DY, 2004) |
| " Selected compounds have also been examined for their activities in inhibiting histamine-induced bronchospasm in anaesthetized guinea pigs." | 3.69 | Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. ( Ashton, MJ; Cook, DC; Fenton, G; Karlsson, JA; Palfreyman, MN; Raeburn, D; Ratcliffe, AJ; Souness, JE; Thurairatnam, S; Vicker, N, 1994) |
| "A new guinea pig model of allergic asthma was used to investigate the effects of low doses of the phosphodiesterase inhibitors, rolipram (phosphodiesterase IV selective), ORG 20241 (N-hydroxy-4-(3,4-dimethoxyphenyl)-thiazole-2-carboximidamide; dual phosphodiesterase III/IV inhibitor with some selectivity for the phosphodiesterase IV isoenzyme), and of theophylline (non-selective) on allergen-induced early and late phase asthmatic reactions, bronchial hyperreactivity to histamine inhalation, and airway inflammation." | 3.69 | Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. ( Meurs, H; Olymulder, CG; Santing, RE; Van der Molen, K; Zaagsma, J, 1995) |
| "The effect of rolipram, an isozyme IV-selective inhibitor of cAMP-specific phosphodiesterase, was evaluated in a guinea pig eye model of tissue eosinophilia." | 3.68 | cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva. ( Newsholme, SJ; Schwartz, L, 1993) |
| "Theophylline has been widely used in the treatment of bronchial asthma mainly due to its bronchodilating effect." | 1.32 | Theophylline attenuates the adhesion of eosinophils to endothelial cells. ( Choo, JH; Kikuchi, I; Nagata, M; Sakamoto, Y; Sutani, A, 2003) |
| " Multiple day dosing also improved activity." | 1.31 | Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. ( Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL, 2000) |
| "Rolipram was characterized for its emetic, behavioral, cardiovascular and pulmonary activities in dogs, to assess its systemic pharmacology and potential bronchodilatory selectivity." | 1.29 | Emetic, central nervous system, and pulmonary activities of rolipram in the dog. ( Evans, DY; Heaslip, RJ, 1995) |
| "Pretreatment with rolipram (10 mg kg-1, i." | 1.29 | Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. ( Cortijo, J; Martí-Cabrera, M; Morcillo, EJ; Ortiz, JL; Vallés, JM, 1996) |
| "Treatment with rolipram, but not theophylline, prevented the increase in responsiveness to inhaled histamine 24 h after antigen challenge." | 1.29 | Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. ( Blake, SM; Gozzard, N; Herd, CM; Higgs, GA; Holbrook, M; Hughes, B; Page, CP, 1996) |
| "4." | 1.29 | The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. ( Alexander, R; Allen, R; Blease, K; Bloxham, D; Boyd, E; Catterall, C; Eaton, M; Gozzard, N; Head, J; Higgs, G; Holbrook, M; Howat, D; Hughes, B; Hughes, P; James, T; Kingaby, R; Lisle, H; Lumb, S; Merriman, M; Owens, R; Perry, M; Russell, A; Smith, B; Wales, M; Warrellow, G, 1996) |
Research
Studies (46)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (30.43) | 18.2507 |
| 2000's | 23 (50.00) | 29.6817 |
| 2010's | 9 (19.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ashton, MJ | 1 |
| Cook, DC | 1 |
| Fenton, G | 1 |
| Karlsson, JA | 1 |
| Palfreyman, MN | 1 |
| Raeburn, D | 1 |
| Ratcliffe, AJ | 1 |
| Souness, JE | 2 |
| Thurairatnam, S | 1 |
| Vicker, N | 1 |
| Hersperger, R | 1 |
| Bray-French, K | 1 |
| Mazzoni, L | 1 |
| Müller, T | 1 |
| Buckley, G | 1 |
| Cooper, N | 2 |
| Dyke, HJ | 2 |
| Galleway, F | 1 |
| Gowers, L | 2 |
| Gregory, JC | 1 |
| Hannah, DR | 1 |
| Haughan, AF | 2 |
| Hellewell, PG | 1 |
| Kendall, HJ | 2 |
| Lowe, C | 2 |
| Maxey, R | 2 |
| Montana, JG | 2 |
| Naylor, R | 2 |
| Picken, CL | 2 |
| Runcie, KA | 2 |
| Sabin, V | 2 |
| Tuladhar, BR | 1 |
| Warneck, JB | 2 |
| Buckley, GM | 1 |
| Galleway, FP | 1 |
| Oxford, J | 1 |
| Peake, JC | 1 |
| Sharpe, A | 1 |
| Kodimuthali, A | 1 |
| Jabaris, SS | 1 |
| Pal, M | 1 |
| Kato, Y | 1 |
| Kawasaki, M | 2 |
| Nigo, T | 2 |
| Nakamura, S | 2 |
| Fusano, A | 2 |
| Teranishi, Y | 2 |
| Ito, MN | 2 |
| Sumiyoshi, T | 2 |
| Matsumoto, S | 1 |
| Toda, H | 1 |
| Nomura, N | 1 |
| Song, G | 1 |
| Zhu, X | 1 |
| Li, J | 1 |
| Hu, D | 1 |
| Zhao, D | 1 |
| Liao, Y | 1 |
| Lin, J | 1 |
| Zhang, LH | 2 |
| Cui, ZN | 2 |
| Hu, DK | 1 |
| Zhao, DS | 1 |
| He, M | 1 |
| Jin, HW | 1 |
| Tang, YM | 1 |
| Song, GP | 1 |
| Schymeinsky, J | 1 |
| Mayer, H | 1 |
| Tomsic, C | 1 |
| Tilp, C | 1 |
| Schuetz, JD | 1 |
| Cui, Y | 1 |
| Wollin, L | 1 |
| Gantner, F | 1 |
| Erb, KJ | 1 |
| Park, K | 1 |
| Lee, JS | 1 |
| Choi, JS | 1 |
| Nam, YJ | 1 |
| Han, JH | 1 |
| Byun, HD | 1 |
| Song, MJ | 1 |
| Oh, JS | 1 |
| Kim, SG | 1 |
| Choi, Y | 1 |
| Yougbare, I | 1 |
| Morin, C | 1 |
| Senouvo, FY | 1 |
| Sirois, C | 1 |
| Albadine, R | 1 |
| Lugnier, C | 1 |
| Rousseau, E | 1 |
| Yang, YL | 1 |
| Hsu, HT | 1 |
| Wang, KH | 1 |
| Han, CY | 1 |
| Chen, CM | 2 |
| Ko, WC | 1 |
| Kenk, M | 1 |
| Thomas, A | 1 |
| Lortie, M | 1 |
| Dekemp, R | 1 |
| Beanlands, RS | 1 |
| Dasilva, JN | 1 |
| Wang, CH | 1 |
| Lin, HC | 1 |
| Lin, CH | 1 |
| Yu, CT | 1 |
| Liu, SL | 1 |
| Huang, KH | 1 |
| Chung, KF | 1 |
| Kuo, HP | 1 |
| Choo, JH | 1 |
| Nagata, M | 1 |
| Sutani, A | 1 |
| Kikuchi, I | 1 |
| Sakamoto, Y | 1 |
| Toward, TJ | 1 |
| Broadley, KJ | 1 |
| Goleva, E | 1 |
| Dunlap, A | 1 |
| Leung, DY | 1 |
| Tang, HF | 1 |
| Song, YH | 1 |
| Chen, JC | 1 |
| Chen, JQ | 1 |
| Wang, P | 1 |
| Jones, NA | 2 |
| Leport, M | 1 |
| Holand, T | 1 |
| Vos, T | 1 |
| Morgan, M | 1 |
| Fink, M | 1 |
| Pruniaux, MP | 1 |
| Berthelier, C | 1 |
| O'Connor, BJ | 3 |
| Bertrand, C | 1 |
| Page, CP | 4 |
| Nejman-Gryz, P | 2 |
| Grubek-Jaworska, H | 2 |
| Glapiński, J | 1 |
| Hoser, G | 1 |
| Chazan, R | 2 |
| Glapińiski, J | 1 |
| Edwards, MR | 1 |
| Haas, J | 1 |
| Panettieri, RA | 1 |
| Johnson, M | 1 |
| Johnston, SL | 1 |
| Hu, A | 1 |
| Nino, G | 1 |
| Grunstein, JS | 1 |
| Fatma, S | 1 |
| Grunstein, MM | 1 |
| Nicholson, CD | 1 |
| Shahid, M | 1 |
| Bruin, J | 1 |
| Barron, E | 1 |
| Spiers, I | 1 |
| de Boer, J | 1 |
| van Amsterdam, RG | 1 |
| Zaagsma, J | 2 |
| Kelly, JJ | 1 |
| Dent, G | 2 |
| Torphy, TJ | 2 |
| Barnette, MS | 1 |
| Hay, DW | 1 |
| Underwood, DC | 1 |
| Lagente, V | 1 |
| Hichami, A | 1 |
| Boichot, E | 1 |
| Martins, MA | 1 |
| Silva, PM | 1 |
| Santing, RE | 1 |
| Olymulder, CG | 1 |
| Van der Molen, K | 1 |
| Meurs, H | 1 |
| Newsholme, SJ | 1 |
| Schwartz, L | 1 |
| Cortijo, J | 2 |
| Bou, J | 1 |
| Beleta, J | 1 |
| Cardelús, I | 1 |
| Llenas, J | 1 |
| Morcillo, E | 1 |
| Gristwood, RW | 1 |
| Heaslip, RJ | 1 |
| Evans, DY | 1 |
| Ortiz, JL | 1 |
| Vallés, JM | 1 |
| Martí-Cabrera, M | 1 |
| Morcillo, EJ | 1 |
| Gozzard, N | 3 |
| Herd, CM | 1 |
| Blake, SM | 1 |
| Holbrook, M | 2 |
| Hughes, B | 3 |
| Higgs, GA | 1 |
| Howat, D | 1 |
| Lisle, H | 1 |
| James, T | 1 |
| Blease, K | 1 |
| Hughes, P | 1 |
| Kingaby, R | 1 |
| Warrellow, G | 1 |
| Alexander, R | 1 |
| Head, J | 1 |
| Boyd, E | 1 |
| Eaton, M | 1 |
| Perry, M | 2 |
| Wales, M | 2 |
| Smith, B | 1 |
| Owens, R | 1 |
| Catterall, C | 1 |
| Lumb, S | 1 |
| Russell, A | 1 |
| Allen, R | 1 |
| Merriman, M | 1 |
| Bloxham, D | 1 |
| Higgs, G | 2 |
| Foissier, L | 1 |
| Lonchampt, M | 1 |
| Cogé, F | 1 |
| Canet, E | 1 |
| Manabe, H | 2 |
| Akuta, K | 2 |
| Okamura, K | 1 |
| Ohmori, K | 2 |
| Hidi, R | 1 |
| Timmermans, S | 1 |
| Liu, E | 1 |
| Schudt, C | 1 |
| Holgate, ST | 1 |
| Djukanović, R | 1 |
| Kawasaki, H | 1 |
| Hammerbeck, DM | 1 |
| McGurran, SM | 1 |
| Radziszewski, PL | 1 |
| Egging, EA | 1 |
| Johnson, DD | 1 |
| Hupperts, AM | 1 |
| Gullikson, GW | 1 |
| Pang, L | 1 |
| Knox, AJ | 1 |
| Dal Piaz, V | 1 |
| Giovannoni, MP | 1 |
| Landells, LJ | 2 |
| Spina, D | 2 |
| Szilagy, CM | 1 |
| Banner, KH | 1 |
| Allen, JM | 1 |
| Doherty, A | 1 |
| Yoshida, N | 1 |
| Shimizu, Y | 1 |
| Kitaichi, K | 1 |
| Hiramatsu, K | 1 |
| Takeuchi, M | 1 |
| Ito, Y | 1 |
| Kume, H | 1 |
| Yamaki, K | 1 |
| Suzuki, R | 1 |
| Shibata, E | 1 |
| Hasegawa, T | 1 |
| Takagi, K | 1 |
| Alexander, RP | 1 |
| Warrellow, GJ | 1 |
| Eaton, MA | 1 |
| Boyd, EC | 1 |
| Head, JC | 1 |
| Porter, JR | 1 |
| Brown, JA | 1 |
| Reuberson, JT | 1 |
| Hutchinson, B | 1 |
| Turner, P | 1 |
| Boyce, B | 1 |
| Barnes, D | 1 |
| Mason, B | 1 |
| Cannell, A | 1 |
| Taylor, RJ | 1 |
| Zomaya, A | 1 |
| Millican, A | 1 |
| Leonard, J | 1 |
| Morphy, R | 1 |
| Allen, RA | 1 |
| Livi, GP | 1 |
| Balcarek, JM | 1 |
| White, JR | 1 |
| Chilton, FH | 1 |
| Undem, BJ | 1 |
Reviews
4 reviews available for rolipram and Asthma
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chr | 2008 |
PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Topics: Animals; Asthma; Brain; Carbon Radioisotopes; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type | 2011 |
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Arthritis, Rheumatoid; Asthma; Cyclic Nucleotide Phosphodiester | 2000 |
Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
Topics: 1-Methyl-3-isobutylxanthine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Asthma; Colforsin; | 1992 |
Other Studies
42 other studies available for rolipram and Asthma
| Article | Year |
|---|---|
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aorta; Asthma; Benzamides; Bronchial Spasm; Eosinophil | 1994 |
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Asthmatic Agents; Asthma; B | 2000 |
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Asthma; Benzamides; Benzofurans; | 2000 |
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Anti-Asthmatic Agents; Asthma; Cyclic Nucleotide Phosph | 2002 |
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Mod | 2013 |
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
Topics: Administration, Oral; Asthma; Emetics; Enzyme Activation; Molecular Structure; Phosphodiesterase 4 I | 2014 |
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Topics: Animals; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Drug Design; | 2017 |
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Inhibitory Concentration 50; Mice; Phosphodiesterase | 2018 |
The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.
Topics: Adenosine; Allergens; Animals; Asthma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP- | 2013 |
Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Fla | 2016 |
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anti-Inflammatory Agents; Asthma | 2011 |
Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
Topics: Animals; Asthma; Binding Sites; Blood Cell Count; Bronchial Hyperreactivity; Bronchoalveolar Lavage | 2011 |
Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.
Topics: Albuterol; Animals; Antigens, CD34; Apoptosis; Asthma; Cell Division; Female; Humans; Male; Methacho | 2003 |
Theophylline attenuates the adhesion of eosinophils to endothelial cells.
Topics: Adult; Asthma; Bronchodilator Agents; Cell Adhesion; Cyclic AMP; Endothelium, Vascular; Eosinophils; | 2003 |
Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram.
Topics: Administration, Inhalation; Animals; Antigens; Asthma; Bronchial Hyperreactivity; Bronchoalveolar La | 2004 |
Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Cell C | 2004 |
Upregulation of phosphodiesterase-4 in the lung of allergic rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Airway Resistance; Animals; Asthma; Cyclic Nucleotide Phosphodi | 2005 |
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Asthma; Benzamides; CD4-Positive T-Lymphocytes; CD | 2007 |
Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Dexamethasone; Guinea Pigs; | 2006 |
[Effect of phosphodiestrase 4 inhibitor (rolipram) on experimental allergic asthma-guinea pig model].
Topics: Administration, Inhalation; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar L | 2006 |
Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen | 2007 |
Prolonged heterologous beta2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Butadienes; Cells, Cultured; Colforsin; Cyclic | 2008 |
Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Asthma; Cattle; Guinea Pigs; Humans; In Vitro T | 1995 |
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antigens; Asthma; Bronchoconstriction; Cell Adhesion; | 1994 |
Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Airway Resistan | 1995 |
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Analysis of Variance; Animals; Asth | 1995 |
cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Asthma; Conjunctiva; Conjunctivitis; Eosinophilia; Eos | 1993 |
Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Animals; Asthma; Bronchodilator Agents; Cyclic Nuc | 1993 |
Emetic, central nervous system, and pulmonary activities of rolipram in the dog.
Topics: Animals; Anxiety; Asthma; Brain; Bronchi; Dogs; Female; Heart Rate; Male; Nadolol; Pentobarbital; Ph | 1995 |
Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.
Topics: Animals; Asthma; Dose-Response Relationship, Drug; Eosinophils; Guinea Pigs; Histamine; Male; Phosph | 1996 |
Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits.
Topics: Airway Resistance; Alternaria; Animals; Anti-Inflammatory Agents; Antigens, Fungal; Asthma; Bronchia | 1996 |
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Airway Resistance; Analysis of Variance; Animals; Asthma; Benza | 1996 |
In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antigens; Asthma; Cyclic AMP; Cyclic Nucleotide Phosph | 1996 |
KF19514, a phosphodieterase 4 and 1 inhibitor, inhibits PAF-induced lung inflammatory responses by inhaled administration in guinea pigs.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Acetylcholine; Animals; As | 1997 |
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
Topics: Albuterol; Asthma; Bucladesine; Chemotaxis, Leukocyte; Colforsin; Cyclic AMP; Humans; Interleukin-8; | 2000 |
The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs.
Topics: Acetylcholine; Administration, Inhalation; Airway Resistance; Aminophylline; Animals; Asthma; Bronch | 2000 |
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Androstadienes; Animals; Asthma; Beclomethasone; Benzamides; Bu | 2000 |
Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagoni | 2000 |
A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Asthma; Case-Control Studies; Guanidines; Humans; | 2000 |
Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adolescent; Adult; Allergens; Asthma; CD4-Positive T-Lymphocyte | 2001 |
Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.
Topics: Adult; Asthma; Cilostazol; Colforsin; Cyclic AMP; Dexamethasone; Humans; In Vitro Techniques; Interl | 2001 |
CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-St | 2002 |